Literature DB >> 3254184

Myasthenia gravis thymus: clinical, histological and culture correlations.

M Schluep1, N Willcox, M A Ritter, J Newsom-Davis, M Larché, A N Brown.   

Abstract

This paper attempts to quantitate immunohistological changes in the myasthenia gravis (MG) thymus and to correlate them with clinical and culture parameters in 40 untreated young onset patients covering a wide range of durations and serum anti-acetylcholine receptor (AChR) antibody titers. Total cellularities of both the thymic cortex and the medulla declined significantly with age. There was some hyperplasia of subcapsular and of medullary epithelial cells, often at the expense of cortex. A combined index of all hyperplastic changes correlated significantly with serum anti-AChR titre. Otherwise histological indices, e.g. of germinal centres (GC) were largely unrelated to any clinical parameters, especially duration of symptoms. Specific anti-AChR synthesis in culture (very closely related to serum titer) correlated better with the medullary lymph node-type T-cell areas; these were more widely prevalent and MG-specific. In contrast, basal and mitogen-stimulated total IgG productivity followed the GC indices more closely. We propose that the variability of GC is due to their dependence on extraneous immune complexes, and we discuss whether they or the T-cell areas are primary or secondary abnormalities. Finally, we conclude that autosensitization in MG with thymic hyperplasia and neoplasia probably arises through separate mechanisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3254184     DOI: 10.1016/0896-8411(88)90067-4

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

1.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

2.  Thymus cells in myasthenia gravis: a two-colour flow cytometric analysis of lymphocytes in the thymus and thymoma.

Authors:  Y Fujii; M Hayakawa; K Nakahara
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

3.  Granzyme B: evidence for a role in the origin of myasthenia gravis.

Authors:  L Casciola-Rosen; A Miagkov; K Nagaraju; F Askin; L Jacobson; A Rosen; D B Drachman
Journal:  J Neuroimmunol       Date:  2008-08-03       Impact factor: 3.478

4.  The thymus in seronegative myasthenia gravis patients.

Authors:  N Willcox; M Schluep; M A Ritter; J Newsom-Davis
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

5.  Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups.

Authors:  Liv Hapnes; Nick Willcox; Bergithe E V Oftedal; Jone F Owe; Nils Erik Gilhus; Anthony Meager; Eystein S Husebye; Anette S Bøe Wolff
Journal:  J Clin Immunol       Date:  2011-11-30       Impact factor: 8.317

Review 6.  Thymus and aging: morphological, radiological, and functional overview.

Authors:  Rita Rezzani; Lorenzo Nardo; Gaia Favero; Michele Peroni; Luigi Fabrizio Rodella
Journal:  Age (Dordr)       Date:  2013-07-23

7.  Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes.

Authors:  M W Nicolle; B Nag; S D Sharma; N Willcox; A Vincent; D J Ferguson; J Newsom-Davis
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.